These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37827257)

  • 41. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES; Howard C; Khan DA; Carmody TJ
    Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of
    Islam F; Magarbeh L; Elsheikh SSM; Kloiber S; Espinola CW; Bhat V; Frey BN; Milev R; Soares CN; Parikh SV; Placenza F; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
    Can J Psychiatry; 2024 Mar; 69(3):183-195. PubMed ID: 37796764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder.
    Kamijima K; Kimura M; Kuwahara K; Kitayama Y; Tadori Y
    Psychiatry Clin Neurosci; 2018 Aug; 72(8):591-601. PubMed ID: 29660207
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
    Demyttenaere K; Andersen HF; Reines EH
    Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of aripiprazole discontinuation in remitted major depressive disorder: a randomized placebo-controlled trial.
    Takeshima M; Umakoshi A; Omori Y; Yoshizawa K; Ogasawara M; Kudo M; Itoh Y; Ayabe N; Mishima K
    Psychopharmacology (Berl); 2024 Aug; 241(8):1555-1563. PubMed ID: 38538921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report.
    Suh JS; Minuzzi L; Raamana PR; Davis A; Hall GB; Harris J; Hassel S; Zamyadi M; Arnott SR; Alders GL; Sassi RB; Milev R; Lam RW; MacQueen GM; Strother SC; Kennedy SH; Frey BN
    Neuroimage Clin; 2020; 25():102178. PubMed ID: 32036277
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram, in patients with major depressive disorder--the navigade switch study].
    Schmitt L; Arbus C; Tonnoir B
    Encephale; 2006; 32(2 Pt 1):270-7. PubMed ID: 16910629
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study.
    Ozaki N; Otsubo T; Kato M; Higuchi T; Ono H; Kamijima K;
    Psychiatry Clin Neurosci; 2015 Jan; 69(1):34-42. PubMed ID: 24965202
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Repetitive transcranial magnetic stimulation combined with antidepressant medication in treatment of first-episode patients with major depression].
    Huang ML; Xu Y; Hu JB; Zhou WH; Wei N; Hu SH; Qi HL; Luo BY
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2011 May; 40(3):286-90. PubMed ID: 21671489
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum amyloid P component level is associated with clinical response to escitalopram treatment in patients with major depressive disorder.
    Yang J; Zhou J; Zhou J; Wang H; Sun Z; Zhu X; He Y; Wong AHC; Liu F; Wang G
    J Psychiatr Res; 2022 Feb; 146():172-178. PubMed ID: 34995992
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial.
    Findling RL; Robb A; Bose A
    J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):468-80. PubMed ID: 24041408
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trial of Psilocybin versus Escitalopram for Depression.
    Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
    N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study.
    Yoo I; Woo JM; Lee SH; Fava M; Mischoulon D; Papakostas GI; Kim EJ; Chung S; Ha JH; Jeon HJ
    J Affect Disord; 2015 Oct; 185():24-30. PubMed ID: 26142691
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.
    Uher R; Frey BN; Quilty LC; Rotzinger S; Blier P; Foster JA; Müller DJ; Ravindran AV; Soares CN; Turecki G; Parikh SV; Milev R; MacQueen G; Lam RW; Kennedy SH;
    J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32558407
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial.
    Ventura D; Armstrong EP; Skrepnek GH; Haim Erder M
    Curr Med Res Opin; 2007 Feb; 23(2):245-50. PubMed ID: 17288677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.